Business UpdateJun 9, 2026, 03:31 PM
Cosmos Health Inaugurates New Production Line, Secures 5-Year Contract
AI Summary
Cosmos Health Inc. announced that its wholly-owned subsidiary, Cana Laboratories, has inaugurated a new, state-of-the-art capsule production line. Concurrently, Cana secured an additional five-year contract manufacturing agreement with Provident Pharmaceuticals to produce 385,000 units of CERTORUN (sertraline hydrochloride) over the period, with an annual volume of 77,000 units. This strategic move is part of Cosmos Health's ongoing investment in modernizing its manufacturing capabilities and aims to generate high-margin, recurring revenue.
Key Highlights
- Cana Laboratories, a Cosmos Health subsidiary, inaugurated a new ACG capsule production line.
- Secured a five-year contract manufacturing agreement with Provident Pharmaceuticals.
- Cana will manufacture 385,000 units of CERTORUN over the five-year period.
- Annual production volume for CERTORUN is 77,000 units.
- CERTORUN will be produced in 50mg/cap and 100mg/cap strengths.
- This agreement builds on Cana's existing relationship with Provident for other products.
- Contract manufacturing is a core pillar of Cosmos Health's long-term growth strategy.
Price Impact
More from COSM